Literature DB >> 9608607

Mechanism of triazolo-benzodiazepine and benzodiazepine action in anxiety and depression: behavioral studies with concomitant in vivo CA1 hippocampal norepinephrine and serotonin release detection in the behaving animal.

P A Broderick1, O Hope, P Jeannot.   

Abstract

1. Real time, in vivo microvoltammetric studies were performed, using miniature carbon-based sensors, to concurrently detect norepinephrine (NE) release and serotonin (5-HT) release, in 2 separate electrochemical signals, within CA1 region of hippocampus in the freely moving and behaving, male, Sprague Dawley laboratory rat. 2. Concurrently, four parameters of open-field behavior, i.e. Ambulations, Rearing, Fine Movements and Central Ambulatory behavior (a measure of anxiety reduction behavior), were assayed by infrared photobeam detection. 3. Time course studies showed that the mechanism of action of the triazolobenzodiazepine (TBZD), adinazolam, (Deracyn) is dramatically different from that of the classical benzodiazepine (BZD), diazepam (Valium, i.e., adinazolam increased, whereas diazepam decreased, 5-HT release within CA1 region of hippocampus in the freely moving and behaving rat. 4. Adinazolam initially increased NE release and then decreased NE release in CA1 region of hippocampus in the freely moving and behaving rat whereas diazepam only decreased the electrochemical signal for NE; the decrease in NE produced by adinazolam was greater than the decrease in NE release produced by diazepam. 5. The Behavioral Activity Patterns, derived from same animal controls, simultaneously with detection of in vivo microvoltammetric signals for NE release and 5-HT release, showed that the BZD, diazepam, exhibited more potent sedative properties than did the TBZD adinazolam. 6. Hippocampal 5-HT and NE release effects of the TBZD, adinazolam, concomitant with behavioral effects lends explanation to the dual anxiolytic/antidepressant properties of the TBZDs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9608607      PMCID: PMC7131360          DOI: 10.1016/s0278-5846(98)00010-4

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  82 in total

1.  Adinazolam, a fast-acting antidepressant, is tolerated during general anesthesia.

Authors:  S C Othmer; E Othmer
Journal:  J Clin Psychopharmacol       Date:  1988-04       Impact factor: 3.153

2.  Electrically evoked noradrenaline release in the rat hypothalamic paraventricular nucleus studied by in vivo electrochemistry: autoregulation by alpha-2 receptors.

Authors:  C Mermet; M F Suaud-Chagny; F Gonon
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

3.  Serotonin function and mechanism of action of antidepressant treatment. Effects of amitriptyline and desipramine.

Authors:  D S Charney; G R Heninger; D E Sternberg
Journal:  Arch Gen Psychiatry       Date:  1984-04

4.  Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.

Authors:  I K Wright; M Heaton; N Upton; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Sensitization of rat forebrain neurons to serotonin by adinazolam, an antidepressant triazolobenzodiazepine.

Authors:  A Turmel; C De Montigny
Journal:  Eur J Pharmacol       Date:  1984-03-23       Impact factor: 4.432

6.  Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

Authors:  D V Sheehan; J Ballenger; G Jacobsen
Journal:  Arch Gen Psychiatry       Date:  1980-01

7.  A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.

Authors:  J J Mann; S F Aarons; P J Wilner; J G Keilp; J A Sweeney; T Pearlstein; A J Frances; J H Kocsis; R P Brown
Journal:  Arch Gen Psychiatry       Date:  1989-01

Review 8.  Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents.

Authors:  S L Dubovsky
Journal:  J Clin Psychiatry       Date:  1994-02       Impact factor: 4.384

Review 9.  Newer antidepressants and the cytochrome P450 system.

Authors:  C B Nemeroff; C L DeVane; B G Pollock
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

10.  Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo.

Authors:  G Laakman; M Faltermaier-Temizel; S Bossert-Zaudig; T Baghai; G Lorkowski
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

View more
  2 in total

1.  Somatization Disorder.

Authors:  Donald M. Hilty; James A. Bourgeois; Celia H. Chang; Mark E. Servis
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

2.  Alcohol, drugs and driving: implications for evaluating driver impairment.

Authors:  Timothy Brown; Gary Milavetz; Daryl J Murry
Journal:  Ann Adv Automot Med       Date:  2013
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.